This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

As an increasing number of people worldwide are living with diabetes, our device and digital therapeutic innovations have the potential to support diabetes management.

Up to 50% of people diagnosed with type 2 diabetes delay starting on insulin5* for more than 2 years6 after it’s recommended.

 
But, with 30 million people with type 2 diabetes worldwide having already taken the positive step to start insulin therapy when it’s needed,7† there are actually 30 million reasons for your patients to say ‘yes’ to insulin.

An early SHIFT in treatment could change lives

 

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.8-10

Connecting medical professionals with useful tools to manage obesity effectively.

Explore a series of articles covering the link between obesity and cardiovascular disease (CVD), the global burden of CVD and the residual CVD risk rising from obesity.13

 

ACTION teens is a global, cross-sectional survey aimed at identifying perceptions, attitudes, behaviours, and barriers to effective obesity care among adolescents living with obesity, their caregivers, and healthcare professionals. Misalignment between ALwO, caregivers, and HCPs — including caregivers' underestimation of the impact of obesity on ALwO and HCPs' misperception of key motivators/barriers for weight loss — suggests a need for improved communication and education.14

Get ready to learn more about our scientific content from renowned experts at EASD 2024 through our publications and 6 exciting industry sessions taking place in Madrid and online.

Visit EASD 2024 Novo Nordisk Science Hub to know more on these sessions including the agenda (available for download), teaser videos and more!

 

Visit Science Hub now!

Roge silvia

Innovation in action: moving forward with basal insulins in T2D

 

Monday 09 September 2024
09.00-11.00 CEST

 

On-demand from:
Tuesday 10 September 2024

Simone Lensbøl

At the crossroads of specialties: Exploring the trends in the holistic, person-centred approach in cardiovascular-kidney-metabolic disease

 

Tuesday 10 September 2024
18.30-20.00 CEST

 

On-demand from:
Wednesday 11 September 2024

Simone Lensbøl

T2D care in the digital era: evidence with once-weekly insulins, CGM and other digital health tools

 

Wednesday 11 September 2024
12.15-12.45 CEST

 

On-demand from:
Thursday 12 September 2024

nn-easd-2024-vicki-mooney.png

Obesity management in the spotlight: how can we ​​achieve patient-centricity? ​​

 

Wednesday 11 September 2024
18.45-20.15 CEST

 

On-demand from:
Thursday 12 September 2024

Nadia Sadi

Breaking the barriers: Addressing the metabolic impact of MASH with multidisciplinary care
 

Thursday 12 September 2024
18.45-19.15 CEST

 

On demand from:
Friday 13 September 2024

nn-easd-2024-guishan-han.png

Management of CKD in T2D – where are we today?


Thursday 12 September 2024

19.45-20.15 CEST

 

On-demand from:
Friday 13 September 2024

EASD 2024 is the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), a non-profit medical scientific association which supports and promotes the application of research in diabetes. The association was founded in 1965 and is one of the largest networks for diabetologists in the world.

The event is open to scientists, physicians, students, postdocs and fellows, allied health professionals, nurses, and others who are interested in the field of diabetes or related diseases.

1.

RYBELSUS® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; March 2024.

2.

Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019 Apr 16;321(15):1466-1480.

3.

Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019 Dec;42(12):2272-2281.

4.

Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.

5.

Rubino A, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–1418.

6.

Hosomura N, et al. Decline of insulin therapy and delays in insulin initiation in people with uncontrolled diabetes mellitus. Diabet Med. 2017;34:1599–1602.

7.

Basu S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(S1):25–33 

8.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

9.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

10.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

11.

Lincoff AM et al. N Engl J Med 2023;D&I:10.1056/NEJMoa2307563.

12.

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec.76(25)2982–3021. Doi: 10.1016/j.jacc.2020.11.010.

13.

Halford JCG, et al. Misalignment among adolescents living with obesity, caregivers, and healthcare professionals: ACTION Teens global survey study. Pediatric Obesity.2022;17:e12957. Available at: https://onlinelibrary.wiley.com/doi/10.1111/ijpo.12957 Last accessed September 2023.

*After failure of non-insulin glucose-lowering medications.5
In a microsimulation of type 2 diabetes burden from 2018 to 2030 across 221 countries, it was estimated that the number of people with type 2 diabetes globally utilising insulin in 2018 was 30,229,435.7

5.

Rubino A, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–1418.

6.

Hosomura N, et al. Decline of insulin therapy and delays in insulin initiation in people with uncontrolled diabetes mellitus. Diabet Med. 2017;34:1599–1602.

7.

Basu S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(S1):25–33 

8.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

9.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

10.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

12.

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec.76(25)2982–3021. Doi: 10.1016/j.jacc.2020.11.010.

13.

Halford JCG, et al. Misalignment among adolescents living with obesity, caregivers, and healthcare professionals: ACTION Teens global survey study. Pediatric Obesity.2022;17:e12957. Available at: https://onlinelibrary.wiley.com/doi/10.1111/ijpo.12957 Last accessed September 2023.

*After failure of non-insulin glucose-lowering medications.5
In a microsimulation of type 2 diabetes burden from 2018 to 2030 across 221 countries, it was estimated that the number of people with type 2 diabetes globally utilising insulin in 2018 was 30,229,435.7


The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.


This material is promotional in nature and is intended exclusively for healthcare professionals with the capacity to prescribe or dispense medicinal products and is developed in accordance with the applicable regulations on the advertising of medicinal products for human use, supported by valid and relevant bibliographic references. Novo Nordisk has reviewed the compliance with the above, as well as the adequacy of the information presented with the corresponding approved SmPCs. If you wish to report an adverse event or technical complaint, please contact us at
012_SpainFarmacov@novonordisk.com.

Before prescribing, please consult the SmPC. Novo Nordisk does not recommend the use of its medicines for indications other than those listed in the SmPC.

This material is intended exclusively for healthcare professionals, so its direct or indirect dissemination through social networks or other media to the general public is not permitted.


Awiqli®

Awiqli® está autorizado por la EMA pero no se encuentra comercializado en España. Este medicamento esta comercializado en otros países.
Awiqli® is authorized by the EMA but is not marketed in Spain. This product is marketed in other countries.


SmartPens

NovoPen Echo® Plus y NovoPen® 6 son productos sanitarios con marcado CE0123 que cumplen con la legislación vigente. Para más información consultar las Instrucciones de Uso de su pluma inteligente. No utilice NovoPen Echo® Plus ni NovoPen® 6 si no ha recibido la formación adecuada por parte de su médico o enfermero. Asegúrese de que sabe administrarse una inyección con seguridad con la pluma antes de comenzar su tratamiento. Compruebe siempre el nombre y el color del cartucho para asegurarse de que contiene el tipo de insulina que necesita. Mantenga siempre su pluma fuera de la vista y del alcance de otros, especialmente de los niños. Si desea informarnos sobre un acontecimiento adverso o reclamación técnica, por favor, dirijase a la dirección 012_SpainFarmacov@novonordisk.com.

NovoPen Echo® Plus and NovoPen® 6 are CE0123 marked medical devices that comply with current legislation. For more information, consult the Instructions for Use of your smartpen. Do not use NovoPen Echo® Plus or NovoPen® 6 if you have not received proper training from your doctor or nurse. Make sure you know how to safely administer an injection with the pen before starting your treatment. Always check the name and color of the cartridge to ensure it contains the type of insulin you need. Always keep your pen out of sight and reach of others, especially children. If you wish to report an adverse event or technical complaint, please go to the address 012_SpainFarmacov@novonordisk.com.

Wegovy® needles

NovoFine® Plus es Producto Sanitario con marcado CE(0123) que cumple con la legislación vigente.
NovoFine® Plus is a Medical Device with CE marking (0123) that complies with current legislation.


ES: ▼ Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificacaión de sospechadas reacciones adversas asociadas a este medicamento.


EN: ▼ This medicinal product is subject to additional monitoring, reporting of suspected adverse reaction associated with this medicinal product is a priority.




The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.


This material is promotional in nature and is intended exclusively for healthcare professionals with the capacity to prescribe or dispense medicinal products and is developed in accordance with the applicable regulations on the advertising of medicinal products for human use, supported by valid and relevant bibliographic references. Novo Nordisk has reviewed the compliance with the above, as well as the adequacy of the information presented with the corresponding approved SmPCs. If you wish to report an adverse event or technical complaint, please contact us at
012_SpainFarmacov@novonordisk.com.

Before prescribing, please consult the SmPC. Novo Nordisk does not recommend the use of its medicines for indications other than those listed in the SmPC.

This material is intended exclusively for healthcare professionals, so its direct or indirect dissemination through social networks or other media to the general public is not permitted.

 

HQ24NNG00118, August 2024